26 results
Thumbnail

D1.44 - A Difficult to Treat Chronic Urticaria With Psychological Stress, High Anti-Thyroglobulin and De-labeling Hypersensitivity Reaction to Cetirizine

Thumbnail

D1.45 - Omalizumab Reduces Anaphylactic Reactions and Facilitates Food Introduction in Food-Allergic Children with Severe Asthma: A Case Report

Thumbnail

D1.48 - Challenging decisions: Feasibility and safety of multiple low-risk drug challenges in a single clinic visit during peri-operative anaphylaxis investigation

Thumbnail

D1.49 - Crossed-reactivity among Proton Pump Inhibitors in Immediate Severe Hipersensitivity Reactions

Thumbnail

D1.50 - Coconut Oil Anaphylaxis after Mucous Exposure, in a Patient with Primary Coconut Allergy

Thumbnail

D1.53 - Anaphylaxis to Beta-Lactams: The Importance of the Oral Challenge Test in Diagnosis

Thumbnail

D1.54 - Nut Allergy in the Spotlight: The Crucial Role of Oral Provocation Tests

Thumbnail

D1.55 - Assembling the Idiopathic Anaphylaxis Puzzle: Where was the secret key for Idiopathic anaphylaxis’s box?

Thumbnail

D1.46 - Allergic Reaction to Quadrivalent Meningococcal Conjugate Vaccine (MCV4): Case Report and Diagnostic Approach

Thumbnail

D1.435 - Eosinophilic diseases: from nasal polyposis, eosinophilic asthma to EGPA (Eosinophilic Vasculitis with PolyAngioitis), evaluation of possible biomarkers of disease evolution

Thumbnail

D1.437 - Frequency of SNPs associated with pharmacogenetic phenotypes in Asthma in two Colombian populations

Thumbnail

D1.439 - Is allergic conjunctivitis tip of the allergic iceberg ?

Thumbnail

D1.440 - Single cell pipeline to improve immune cell annotation through comparison of multiple bioinformatic methods

Thumbnail

D2.294 - Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023

Thumbnail

D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters

Thumbnail

D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch

Thumbnail

D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria

Thumbnail

D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway

Thumbnail

D2.300 - Fixed Drug Eruption related to the use of NSAIDs

Thumbnail

D2.302 - Non - immediate hypersensitivity to oxybutynin, first confirmed case with lymphocyte transformation test